Form 4: BioNTech CFO Reports Stock Option and PSU Transactions

BioNTech SE's Chief Financial Officer, Ramon Zapata Gomez, has reported the acquisition of stock options and performance share units.

Summary

• Ramon Zapata Gomez, Chief Financial Officer of BioNTech SE, has filed a Form 4 detailing transactions related to stock options and performance share units (PSUs).
• On May 12, 2026, Mr. Gomez acquired 18,879 stock options with an exercise price of EUR 89.38, subject to adjustments.
• These options vest annually over four years, commencing on the first anniversary of the grant date, and become exercisable four years after the grant date, contingent on performance and continued service.
• Additionally, 15,103 Performance Share Units (PSUs) were acquired on the same date.
• Each PSU is economically equivalent to one ordinary share and can be settled in ordinary shares, ADSs, or cash.
• PSUs also vest annually over four years and become exercisable four years after the grant date, dependent on specific performance targets and continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it pertains to routine executive compensation and equity awards rather than significant financial performance or strategic shifts.

Positives

• The acquisition of stock options and PSUs by the CFO indicates a continued alignment of management's interests with those of shareholders.
• The vesting schedules and performance conditions attached to these awards suggest a focus on long-term value creation and achievement of company goals.

Negatives

• The filing does not contain any negative financial or operational information; it solely reports on executive compensation and equity awards.

Risks

• The value of the stock options and PSUs is subject to market fluctuations and the achievement of performance targets, which introduces investment risk for the executive.
• The exercise price of the options is subject to adjustment, which could impact the ultimate profitability of the options.

Future Outlook

The future outlook for the stock options and PSUs is contingent on the company's stock performance, the achievement of specific performance targets, and the continued service of the reporting person.

Industry Context

StockSavvy.ai notes that the issuance of stock options and performance share units to key executives like the CFO is a common practice in the biotechnology and pharmaceutical sectors to incentivize long-term performance and align executive compensation with shareholder value. BioNTech SE, as a leading mRNA-based therapeutics company, utilizes such instruments to retain talent and drive innovation in a highly competitive industry.

Stakeholder Impact

• Shareholders: The alignment of executive interests with shareholder value through equity awards can be seen as positive, though the dilutive effect of future share issuances upon exercise should be considered.
• Employees: The company's ability to attract and retain key talent like the CFO is supported by competitive compensation packages, which indirectly benefits employees through stable leadership.
• Management: The CFO benefits from potential future gains on stock options and PSUs, contingent on company performance and market conditions.

Next Steps

• The stock options may become exercisable starting May 12, 2030, subject to vesting and performance conditions.
• The performance share units may be settled starting May 12, 2030, subject to vesting and performance conditions.
• The stock options expire on May 12, 2036.

Key Dates

Keywords

BioNTech SE, BNTX, Form 4, Stock Options, Performance Share Units, PSU, Executive Compensation, Beneficial Ownership, Ramon Zapata Gomez, CFO